Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer

Radiation Oncology

  ^{1    2    3    4    5} 

[1] 0000 0001 0807 1581, grid.13291.38, Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 37# of Wainan Guoxue Lane, 610041, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, 610041, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 37# of Wainan Guoxue Lane, 610041, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, 610041, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 37# of Wainan Guoxue Lane, 610041, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 37# of Wainan Guoxue Lane, 610041, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, Department of Radiation Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, Department of Abdominal Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, 37# of Wainan Guoxue Lane, 610041, Chengdu, Sichuan Province, People’s Republic of China;0000 0001 0807 1581, grid.13291.38, West China Biostatistics and Cost-Benefit Analysis Center, Sichuan University, 610041, Chengdu, Sichuan Province, People’s Republic of China;

关键词: Cost-effectiveness;    Short-course radiotherapy;    Long-course chemoradiotherapy;    Rectal cancer;    Hypofractional radiotherapy;   

DOI  :  10.1186/s13014-019-1319-8

来源: publisher

【 摘 要 】

PurposeTo evaluate the cost-effectiveness of preoperative short-course radiotherapy (SCRT, 5 × 5 Gy) plus FOLFOX4 versus long-course oxaliplatin and bolus of fluorouracil based preoperative long-course chemoradiotherapy (LCCRT, 50.4 Gy in 28 fractions) in the management of cT4 or advanced cT3 rectal cancer (RC), both of which have been reported to achieve similar clinical effect in the NCT00833131 trial.Materials and methodsA Markov decision-analytic model compared SCRT plus chemotherapy and LCCRT, by simulating three health states (disease-free survival (DFS), progressive disease (PD) and death). The primary outcomes were quality-adjusted life months (QALMs), costs, and incremental cost-effectiveness ratios (ICERs). Transition probabilities were based on the NCT00833131 trial. The costs were calculated from a Chinese payers’ perspective. Strategies were evaluated with a willingness-to-pay (WTP) threshold of $2370.47 (3 × GDP) per QALM gained. Sensitivity analysis was performed to model uncertainty in these parameters.ResultsThe overall costs for SCRT plus chemotherapy and LCCRT were $78,937 and $38,140 with effectiveness of 29.92 QALMs and 22.99 QALMs, respectively. SCRT plus chemotherapy increased costs and QALM by $40,797.34 and 6.93 compared to LCCRT, resulting in an ICER of $5884.56/QALM gained. In the DFS state, the whole cost for SCRT plus chemotherapy and LCCRT were $11,490.03 and $10,794.06 with an effectiveness of 21.70 QALMs and 19.65 QALMs, respectively. SCRT plus chemotherapy increased cost and QALM by $695.97 and 2.05 compared to LCCRT, resulting in a ICER of $339.50/QALM gained, which below the WTP. The utility associated with the DFS state was the most influential factor on the cost-effectiveness of SCRT plus chemotherapy. When the cost of PD state below $1920, the ICER of SCRT compared with LCCRT below the WTP.ConclusionCompared with LCCRT, SCRT plus chemotherapy is a more cost-effective strategy for locally advanced resectable RC in the DFS state as well as in the all states when the cost of PD state below $1920.

【 授权许可】

CC BY